Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated a ‘Neutral’ rating on the stock and raised the price target to $130 from $119. The research firm’s neutral stance comes amid skepticism about the commercial opportunity of the company’s Alzheimer’s disease treatment, Leqembi.

Biogen (BIIB) Price Target Hiked to $130 at UBS amid Leqembi Development

The research firm remains on the sidelines regarding the company’s commercial opportunity and clinical data assessment around Leqembi. Consequently, its neutral rating underscores a cautious stance on the prospects for Alzheimer’s disease treatment.

Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance dosing could offer a new option for the ongoing treatment of early Alzheimer’s disease.

Biogen Inc. (NASDAQ:BIIB) is a global biotechnology company that focuses on researching, developing, and manufacturing therapies for neurological diseases. It leverages AI and machine learning to accelerate drug discovery, optimize clinical trials, and enhance operational efficiency. They are actively involved in utilizing AI to comprehend complex neurological diseases and to improve patient care.

While we acknowledge the potential of BIIB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIIB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Farmland and Agriculture Stocks to Buy According to Billionaires and 10 Best Stocks to Buy Amid Gold Rally.

Disclosure: None. This article is originally published at Insider Monkey.